We previously reported that the (1®3)-branched (1®6)-bglucan termed D-Fraction, extracted from the fruit body of the maitake mushroom (Grifola frondosa) ( Fig. 1) , is a biological response modifier (BRM) like lentinan, which is found in Letinus edodes. [1] [2] [3] These polysaccharides enhance the activity of immunocompetent cells such as macrophages, helper T cells, and cytotoxic T cells, which attack tumor cells. These effects of BRMs led us to hypothesize that oral administration of D-Fraction would be an effective treatment for cancer patients. Orally administered D-Fraction was shown to reduce tumor size in mice, without causing unwanted side effects.
gesting that macrophages and T cells were activated by DFraction. In addition, D-Fraction is revealed to be effective for human immunodeficiency virus (HIV) infection 5) and listeriosis, 6) by reinforcing the immune system. These results indicate that one network of the immuno-response pathway by which D-Fraction enhances anti-tumor effects is dependent on an adaptive immunity associated with cytotoxic T cell activation.
Natural killer (NK) cells rapidly recognize and lyse a large variety of tumor or virus-infected cells, without the need for either prior sensitization or MHC-dependent recognition, which is different from cytotoxic T cell. 7) Pham-Nguyen et al. have reported that the early NK cell response alone is not sufficient for tumor clearance, and that both T cells and NK cells are required in the development of the long-term survival in the hepatic tumor model by IL-12-mediated gene therapy. 8) In our clinical study, we also found that D-Fraction activated NK cells in lung, breast and liver carcinoma patients for long periods of time, exceeding one year (Table 1) . To investigate maintenance of NK cell activation by D-Fraction, we examined NK cell activation in MM-46 carcinomabearing mice treated with D-Fraction for 19 d. Our data in this paper may support a critical role for NK cell activation in immunotherapy with D-Fraction for cancer patients.
MATERIALS AND METHODS

Materials
For the detection of human NK activity, chromium-51 (Daiichi Kagaku Yakuhin Co., Tokyo) and lymphopacel (dϭ1.077) (IBL Co., U.S.A.) were prepared.
Animals Male C3H/HeN mice (4-weeks-old) were obtained (Japan Crea Co., Osaka) and were raised for one week before being used for experiments. Food and water were given freely to these mice until used for experiments.
Cells MM-46 carcinoma cells were kindly donated by Dr. Kanki Komiyama.
51
Cr labeled K-562 cells were used as target cells of human NK.
Preparation of D-Fraction D-Fraction was prepared from the dried powder of the fruit body of maitake mushrooms (Grifola frondosa) (Yukiguni Maitake Co., Niigata), according to the method described in our previous paper. 6) The level of LPS contained in D-Fraction was determined by using Endospecy ES-20S Set (Seikagaku Industry Co., Tokyo), and the ratio (%) of LPS in D-Fraction was less than Detection of Human NK Cell Activity NK cells (1ϫ 10 6 ) obtained from blood using the Conray-Ficoll method 9) were mixed with 2ϫ10 7 of 51 Cr-labelled K-562 (target cell of NK cell) cells in a tube. After incubation for 1 h, release of 51 Cr into the culture supernatant was detected using a gcounter. NK activity was calculated as: NK activity (%)ϭ [(experimental releaseϪspontaneous release) cpm/(max-releaseϪspontaneous release) cpm (by 1 N HCl treatment)]ϫ 100.
RESULTS AND DISCUSSION
Effects of D-Fraction on MM46-Carcinoma Cell Growth
On the 20th day of D-Fraction administration to MM-46 tumor-bearing mice, D-Fraction significantly decreased tumor growth as compared with mice administered phosphate bufferent saline (PBS), when the T.I.R. was 82% (Fig. 2) . The effect of D-Fraction was also investigated in C3H/HeJ mice that are non-response to LPS; the T.I.R. was 78%. These results indicated that D-Fraction inhibited the growth of tumor.
Effects of D-Fraction on NK Cell Activation D-Fraction has already been reported to enhance cellular immunity by stimulating cells such as macrophages, helper T cells and cytotoxic T cells.
2) To detect NK cell activation, we examined IFN-g and TNF-a release from whole spleen cells on the 20th day of D-Fraction administration by mouse IFN-g and TNF-a ELISA kits (Genzyme Co., Minneapolis, U.S.A.). As shown in Figs. 3A and 3B, levels of IFN-g and TNF-a were significantly increased by 1.5-and 2.5-fold, respectively, compared to control mice. Intracellular expression of TNF-a in splenic NK cells under D-Fraction administration was also investigated using flow cytometric analysis. To detect NK cells, 2ϫ10 6 cells were stained with R-PE-conjugated PanNK and Cy-Chrom TM -conjugated CD3e antibodies (PharMingen Co., San Diego, CA, U.S.A.) and CD3e negative and PanNK positive was determined to represent the NK cell. Fluorescein isothiocyanate (FITC)-conjugated TNF-a antibody (PharMingen Co.) was used for detecting TNF-a expression in NK cells. After staining, NK cells expressing TNF-a were analyzed using a FACSCalibur analyzer (Beckton Dickinson Co., Grenoble, France) and histograms were calculated with CellQuest software (Becton Dickinson, Mountain View, CA, U.S.A.). As shown in Fig. 3C , D-Fraction administration resulted in a 1.3-fold increase in intracellular TNF-a expression in splenic NK cells compared to control mice. TNF-a is a cytokine released from activated NK cells in the same way as IFN-g, 10, 11) and has various functions relating to inflammatory and cytotoxic reactions, in addition to cytotoxicity and the ability to directly cause hemor- 
Figs. 3A and 3B. Effects of D-Fraction on Release of IFN-g or TNF-a from Whole Spleen Cells in MM-46 Carcinoma-Bearing Mice
On day 20 in mice administered D-Fraction (5 mg/kg/d) or PBS (Ϫ) i.p., splenocytes were collected according to previously described methods. 6) Splenocytes were plated at 1ϫ10 6 cells/well in a 96-well plate and cultured with Con A (10 mg/ml) for 24 h in 5% CO 2 at 37°C. After activation, levels of INF-g and TNF-a in culture supernatant were assessed using ELISA. Data are expressed as meanϮS.E.M. of 4-8 experiments. **, pϽ0.01; ***, pϽ0.001 compared to control mice (Student's t-test). was assessed. When cells were treated with D-Fraction (500-1000 mg/ml) for 24 h, the amount of IL-12 released significantly exceeded basal levels (0 mg/ml D-Fraction) (Fig.  4) . Also, the effect of D-Fraction on IL-12 production was investigated in vitro using peritoneal macrophages from normal C3H/HeJ mice. When the normal peritoneal macrophages were stimulated with D-Fraction (500 mg/ml) for 24 h, IL-12 production showed an increase compared with that of the control (data not shown). These results suggested that the long-term anti-tumor effects of D-Fraction are attributable to activation of NK cells via macrophage-derived IL-12, and to T cell activation. NK cells may be further activated by INF-g released from not only themselves but also activated T cells.
Effect of D-Fraction on the Activation of NK Cells in Cancer Patients
We concluded that D-Fraction was safe with no toxicity according to data confirmed by the Consumer Product Testing Co. Then, a non-randomized clinical trial of D-Fraction was conducted to check the effect in NK cells of 8 cancer patients, who agreed to the trial. As shown in Table 1 , the NK cell activities of these patients were enhanced 1.2-2.7 times by treatment with D-Fraction. Even though these tests were limited and in a non-controlled trial, these results indicated that D-Fraction was effective for activation of NK in cancer patients.
In conclusion, D-Fraction represents an important BRM for NK cells by enhancing IL-12 release from macrophages. In immunotherapy using D-Faction for cancer patients, NK cells are responsible for early anti-tumor responses, while both NK and T cells are responsible for long-term anti-tumor responses. Although the dependence of the immune system on NK cells requires further study, our results also indicate the possibility of immunotherapy by various agents, which enhance the activity of NK cells for cancer patients. 
